endothelin-1 and Gout

endothelin-1 has been researched along with Gout* in 2 studies

Trials

1 trial(s) available for endothelin-1 and Gout

ArticleYear
[Antihypertensive therapy optimization and endothelial function in patients with gout and chronic urate tubulointerstitial nephritis].
    Terapevticheskii arkhiv, 2010, Volume: 82, Issue:6

    to characterize the markers of endothelial dysfunction and the effect of antihypertensive drugs on them in patients with chronic urate tubulointestinal nephritis (UTIN) and articular gout.. The study enrolled 81 patients aged 39 to 59 years with gout and urate nephropathy. All the patients were diagnosed as having grade 1-2 arterial hypertension. A lower glomerular filtration rate (GFR) was noted in 49.9%; microalbuminuria (MAU) and elevated serum endothelin-1 (ET-1) levels were recorded in all the patients. Combination antihypertensive therapy based on the use of angiotensin-converting enzyme (ACE) inhibitors and/or an angiotensin II receptor blocker (ARB) in combination with calcium channel blockers was performed during 12 months. The time course of changes in blood pressure, the parameters of target organ lesion, and the markers of endothelial dysfunction were monitored.. Before the study, all the examinees were found to have MAU and increased serum ET-1, which are regarded simultaneously as signs of renal lesion and as markers of endothelial function. A combination of an ACE inhibitor or an ARB could diminish albuminuria and reduce ET-1 concentrations, lower systolic and diastolic blood pressure significantly, and increase GFR.. The patients with articular gout and chronic UTIN are observed to have signs of endothelial dysfunction eliminated by combination antihypertensive therapy.

    Topics: Angiotensin II Type 2 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biomarkers; Calcium Channel Blockers; Drug Therapy, Combination; Endothelin-1; Endothelium, Vascular; Female; Gout; Humans; Hypertension; Male; Middle Aged; Nephritis, Interstitial; Serum Albumin; Treatment Outcome; Uric Acid

2010

Other Studies

1 other study(ies) available for endothelin-1 and Gout

ArticleYear
[Peripheral vessel wall changes in hypertensive patients with gout].
    Terapevticheskii arkhiv, 2016, Volume: 88, Issue:5

    To investigate the specific features of arterial wall endothelial dysfunction and stiffness in patients with hypertension concurrent with gout.. A total of 54 patients were examined and divided into 2 groups. A study group consisted of 33 hypertensive patients with gout and a comparison group included 21 hypertensive patients without hyperuricemia. The patients did not differ in blood pressure (BP) readings. Uric acid was determined by the reaction with tungstophosphoric solution AT (Reagent, Dnepropetrovsk, Ukraine). The validity of results was checked using the control sera (Biocont C, Russia). Enzyme immunoassays and Doppler studies were used to investigate peripheral vasoregulation. Body mass index, intima-media thickness (IMT), pulse wave velocity (PWV), cardio-ankle vascular index (CAVI), endothelin-1 (ET-1), and endothelium-dependent vasodilation (EDVD) were determined.. All the studied indicators have directly or indirectly a negative impact, by deteriorating the function of the vessel wall. The found arterial structural changes suggest that there is an early atheromatous process in the arterial wall of hypertensive patients with gout. Addition of gout promotes endothelial dysfunction and worsens the course of hypertension. An elevation of indicators, such as PWV, CAVI, and ET-1 levels, has the poorest prognosis for the course of hypertension.. The determination of CAVI, PWV, ET-1 levels, arterial stiffness index along with additional criteria, such as EDVD and IMT, may be used as criteria for a cardiovascular risk in hypertensive patients.. Цель исследования. Изучение особенностей дисфункции эндотелия и жесткости артериальной стенки у больных артериальной гипертонией (АГ) в сочетании с подагрой. Материалы и методы. Обследовали 54 больных, которых разделили на 2 группы. Основную группу составили 33 пациента с АГ и подагрой, группу сравнения - 21 пациент с АГ без гиперурикемии. По уровням артериального давления (АД) больные не различались. Мочевую кислоту определяли в реакции с фосфорновольфрамовым раствором АТ 'РЕАГЕНТ' (Днепропетровск, Украина). Достоверность результатов проверяли на контрольных сыворотках фирмы 'Биоконт С' (Россия). Использованы иммуноферментные и допплерометрические методы исследования вазорегуляции периферических сосудов. Определяли индекс массы тела, толщину комплекса интима-медиа (ТИМ), скорость распространения пульсовой волны (СРПВ), сердечно-лодыжечный сосудистый индекс (СЛСИ), эндотелин-1 (ЭТ-1), зависимую от эндотелия вазодилатацию (ЗЭВД). Результаты. Все исследуемые показатели, прямо или опосредованно, оказывают неблагоприятное воздействие, ухудшая функцию сосудистой стенки. Выявленные структурные изменения в артериях свидетельствуют о наличии раннего атероматозного процесса в артериальной стенке у больных АГ с подагрой. Присоединение подагры способствует дисфункции эндотелия и ухудшают течение АГ. Неблагоприятный прогноз для течения АГ с подагрой имеет повышение таких показателей, как СРПВ, СЛСИ и уровень ЭТ-1. Заключение. Определение СЛСИ, СРПВ, уровня ЭТ-1, индекса жесткости артерий наряду с такими дополнительными критериями, как ЗЭВД и ТИМ, можно использовать в качестве критериев риска развития сердечно-сосудистых осложнений у больных АГ.

    Topics: Adult; Comorbidity; Endothelin-1; Endothelium, Vascular; Female; Gout; Humans; Hypertension; Male; Middle Aged; Peripheral Arterial Disease; Pulsatile Flow; Pulse Wave Analysis; Ultrasonography; Vascular Stiffness

2016